Results 81 to 90 of about 6,889,682 (318)
Econometric estimation of country-specific hospital costs
Cost Effectiveness and Resource Allocation, 2003 Information on the unit cost of inpatient and outpatient care is an essential element for costing, budgeting and economic-evaluation exercises. Many countries lack reliable estimates, however.
Murray Christopher JL +2 more
doaj +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Biosimilar medicines and cost-effectiveness
ClinicoEconomics and Outcomes Research, 2011 Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj
Cost of clinical events in health economic evaluations in Germany: a systematic review
Cost Effectiveness and Resource Allocation, 2012 Guidance from the Institute for Quality and Efficiency in Health Care (IQWiG) on cost estimation in cost–benefit assessments in Germany acknowledges the need for standardization of costing methodology.
Scheuringer Monika +3 more
doaj +1 more source
Some reflections on the use of inappropriate comparators in CEA
Cost Effectiveness and Resource Allocation, 2020 Although the choice of the comparator is one of the aspects with a highest effect on the results of cost-effectiveness analyses, it is one of the less debated issues in international methodological guidelines. The inclusion of an inappropriate comparator
José Antonio Sacristán +4 more
doaj +1 more source
, 2017 Economic evaluation of healthcare programs seeks to compare treatments and preventive measures in terms of their efficiency, that is, their ability to generate health and well-being relative to the costs incurred. This chapter provides an introduction to one particular but widely used evaluation technique: cost-effectiveness analysis (CEA).
Luyten, Jeroen, Henderson, Cate
openaire +3 more sources
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Cost Effectiveness and Resource Allocation, 2018 Background Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of ...
Kevin Marsh +3 more
doaj +1 more source
Clinical and Translational Gastroenterology, 2017 OBJECTIVES: Hepatocellular carcinoma (HCC) surveillance with biannual ultrasound is currently recommended for all patients with cirrhosis. However, clinical implementation of this “one‐size‐fits‐all” approach is challenging as evidenced by its low ...
N. Goossens +8 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués +3 more
wiley +1 more source